@glpbabe's rapid weight loss claims need context

What does this video actually claim?

@glpbabe posted daily weight measurements showing a 5.2-pound loss over one week after starting "Reta" (retiratide, a GLP-1/GIP dual agonist). The TikTok tracks weight dropping from 190 pounds to 184.8 pounds across six consecutive days.

The post uses the hashtag category for testosterone replacement therapy, which seems misplaced since retiratide is a weight management medication, not a hormone therapy. The video presents raw scale numbers without context about expected timelines or typical response patterns.

Is this weight loss pattern realistic?

Yes, but it's mostly water weight and doesn't represent the drug's actual fat-burning effects. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed tirzepatide's weight loss occurs gradually over months, not days.

Rapid initial drops are common with GLP-1 receptor agonists due to reduced food intake, slower gastric emptying, and glycogen depletion. The 15mg tirzepatide dose in SURMOUNT-1 produced 20.9% weight loss, but that happened over 72 weeks.

Real fat loss from tirzepatide typically shows up after 4-8 weeks of consistent use. What @glpbabe documented is normal early response, not the drug's primary mechanism.

What's missing from this picture?

The creator skipped important context about starting doses and realistic expectations. Tirzepatide typically begins at 2.5mg weekly for four weeks before increasing.

Daily weigh-ins can be misleading because normal weight fluctuations range from 2-4 pounds due to hydration, sodium intake, and hormonal changes. The SURMOUNT trials measured participants monthly, not daily, for good reason.

@glpbabe also doesn't mention side effects. In SURMOUNT-1, 81% of participants experienced gastrointestinal issues including nausea, vomiting, and diarrhea. These symptoms often contribute to rapid early weight loss through reduced appetite and fluid loss.

What should you actually expect?

Sustainable results from tirzepatide take time and proper medical supervision. The drug works by mimicking GLP-1 and GIP hormones to regulate blood sugar and slow digestion.

Clinical trials show most significant weight loss occurs between weeks 12-72. The 10mg dose produced 19.5% weight loss, while 15mg reached 20.9% in SURMOUNT-1. But these numbers represent medically supervised treatment with lifestyle modifications.

Don't judge tirzepatide's effectiveness by your first week's scale readings. Focus on consistent dosing, managing side effects, and working with healthcare providers to adjust treatment as needed.